Why is the EMA's approval of this specific commercial GP2 lot important for Greenwich LifeSciences?

The approval creates a uniform manufacturing standard for the international Phase III trial. By utilizing the exact same commercial lot across all active United States and European clinical sites, the company eliminates potential regional product variations, drastically streamlining data consistency and logistics for regulatory reviews.

What specific disease indication and patient population are targeted in the FLAMINGO-01 trial?

The Phase III trial is evaluating the safety and efficacy of GLSI-100 in HER2/neu-positive breast cancer patients who have residual disease or high-risk pathologic complete responses following standard surgery. Eligible participants must have completed their baseline neoadjuvant and postoperative adjuvant trastuzumab-based treatments.

How many active clinical sites are currently participating in the trial, and how has that footprint shifted?

The trial's global footprint has expanded from 160 sites to an estimated 170 to 180 clinical locations spread across the United States and Europe. Within the domestic U.S. sector, approximately 40 to 50 active institutions have already been supplied with the newly approved commercial vials and have actively begun patient dosing.

What is the underlying mechanism of action behind the GP2 therapeutic candidate?

GP2 is a 9-amino acid transmembrane peptide derived from the HER2/neu protein, which is expressed in roughly 75% of all breast cancers. When delivered alongside the immune stimulant GM-CSF, the compound triggers targeted T-cell activation to recognize and destroy microscopic recurring cancer cells before they cause metastatic disease.

What subsequent international regulatory steps is the company pursuing next?

Following the finalized clearances from the FDA and the EMA, corporate management has initiated separate and independent regulatory filing tracks in adjacent markets. The clinical teams are actively submitting identical manufacturing, stability, and quality-control dossiers to secure lot approvals from health authorities in the United Kingdom and Canada.

Image for illustrative purposes only. Not a real photo.

Greenwich LifeSciences secures European approval for Phase 3 asset lot

Written by Isaac FrancisPublished Jul 9, 2026, 10:15 AM

The European Medicines Agency authorized the use of Greenwich's commercially manufactured GP2 lot.
The clinical validation enables unified product distribution across all European and United States sites.
Global active trial sites have scaled to between 170 and 180 locations to accelerate patient treatment.

Greenwich LifeSciences (NASDAQ:GLSI) announced today that the European Medicines Agency (EMA) has completed its regulatory review and approved the use of its commercially manufactured GP2 immunotherapy lot for the ongoing Phase III FLAMINGO-01 clinical trial.

The decision standardizes the late-stage trial's global supply chain.

The United States Food and Drug Administration (FDA) previously approved this exact commercial lot, which is already being administered to patients across 40 to 50 active clinical sites in the U.S.

"The EMA’s alignment allows us to efficiently streamline global logistics, utilizing the exact same high-quality commercial batch across both continents," the company indicated in a strategic clinical briefing.

Following the international regulatory milestone, Greenwich LifeSciences has initiated shipments of the GP2 vials directly to European hospital pharmacies.

The biopharmaceutical developer confirmed that its global trial footprint has expanded from a baseline of 160 locations to approximately 170 to 180 active or activating clinical sites.

All participating medical networks in the U.S. and Europe are expected to use this single, uniform manufacturing lot.

Building on this momentum, the Texas-based firm is aggressively seeking independent regulatory clearances to introduce the same commercial lot into upcoming trial sites across the United Kingdom and Canada.

The FLAMINGO-01 study evaluates GLSI-100 (GP2 combined with GM-CSF), a specialized peptide immunotherapy engineered to stimulate the immune system to prevent metastatic breast cancer recurrences in HER2/neu-positive patients following surgery.

Greenwich LifeSciences secures European approval for Phase 3 asset lot

Frequently asked questions

Assets related to this article